Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

by Jessica C Hassel, Celeste Lebbe, Paul Nghiem, Felix Kiecker, Sandra P D'Angelo, Andrew S Brohl, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Laurent Mortier, Jean-Jacques Grob, Nicola Fazio, Natalie Prinzi, Glenn J Hanna
Published 2021-07-01